CN104159591A - 红细胞的处理 - Google Patents

红细胞的处理 Download PDF

Info

Publication number
CN104159591A
CN104159591A CN201280066237.9A CN201280066237A CN104159591A CN 104159591 A CN104159591 A CN 104159591A CN 201280066237 A CN201280066237 A CN 201280066237A CN 104159591 A CN104159591 A CN 104159591A
Authority
CN
China
Prior art keywords
nitric oxide
red blood
blood cell
cell sample
transfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280066237.9A
Other languages
English (en)
Chinese (zh)
Inventor
W.M.扎波尔
B.于
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN104159591A publication Critical patent/CN104159591A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A61M2202/0275—Nitric oxide [NO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0429—Red blood cells; Erythrocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201280066237.9A 2011-11-07 2012-11-06 红细胞的处理 Pending CN104159591A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556661P 2011-11-07 2011-11-07
US61/556,661 2011-11-07
PCT/US2012/063690 WO2013070592A1 (en) 2011-11-07 2012-11-06 Treatment of red blood cells

Publications (1)

Publication Number Publication Date
CN104159591A true CN104159591A (zh) 2014-11-19

Family

ID=48290479

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280066237.9A Pending CN104159591A (zh) 2011-11-07 2012-11-06 红细胞的处理

Country Status (6)

Country Link
US (1) US9572833B2 (enExample)
EP (1) EP2776047A4 (enExample)
JP (1) JP6389125B2 (enExample)
CN (1) CN104159591A (enExample)
HK (1) HK1200355A1 (enExample)
WO (1) WO2013070592A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111919835A (zh) * 2020-08-06 2020-11-13 温州医科大学 维持红细胞活性的保存液

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12529737B2 (en) * 2019-03-25 2026-01-20 Ronald Day Systems and methods for using improved contrast agent in performing and MRI
WO2021015235A1 (ja) * 2019-07-22 2021-01-28 学校法人北里研究所 透析装置
EP4123303A1 (en) * 2021-07-20 2023-01-25 German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH Non-invasive method for predicting the hemoglobin and iron content in prbc units
EP4633693A1 (en) 2022-12-16 2025-10-22 Fresenius Medical Care Holdings, Inc. Systems and methods for using nitric oxide in dialysis
WO2025212681A1 (en) * 2024-04-01 2025-10-09 Ohio State Innovation Foundation Compositions, kits, and methods for the preservation of blood products

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5423738A (en) * 1992-03-13 1995-06-13 Robinson; Thomas C. Blood pumping and processing system
WO2001009616A2 (en) * 1999-08-02 2001-02-08 Duke University Method for determining physiological effects of hemoglobin
US20020037839A1 (en) * 1995-09-15 2002-03-28 Jonathan S. Stamler No-modified hemoglobins and uses therefor
WO2003066109A1 (en) * 2002-02-08 2003-08-14 Gambro, Inc. Nitric oxide in a pathogen inactivation process
WO2003102575A1 (en) * 2002-05-29 2003-12-11 Duke University Measuring nitric oxide in blood gases and treatments based thereon
US20100239692A1 (en) * 2007-09-20 2010-09-23 Kim-Shapiro Daniel B Methods of treatment for hemolysis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
DE69127756T2 (de) 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5536241A (en) 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
DE59409834D1 (de) 1993-04-17 2001-09-27 Messer Griesheim Austria Ges M Gerät zur kontrollierten Zudosierung von NO zur Atemluft von Patienten
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
GB9320978D0 (en) 1993-10-12 1993-12-01 Higenbottam Timohy W Nitric oxide treatment
SE9303486L (sv) 1993-10-22 1995-04-23 Siemens Elema Ab Metod vid bestämning av den funktionella residualkapaciteten för lungor samt en ventilatoranordning för bestämning av den funktionella residualkapaciteten
US5558083A (en) 1993-11-22 1996-09-24 Ohmeda Inc. Nitric oxide delivery system
SE503876C2 (sv) 1994-11-30 1996-09-23 Kjell Alving Detektion av inflammatoriska tillstånd i tarmkanalen genom att mäta kväveoxidhalten i ett prov taget ur tarmlumen
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5823180A (en) 1995-04-03 1998-10-20 The General Hospital Corporation Methods for treating pulmonary vasoconstriction and asthma
JP2000510448A (ja) * 1996-04-05 2000-08-15 ザ ジェネラル ホスピタル コーポレーション 異常ヘモグロビン症の治療
WO1998008500A1 (en) 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
CA2278784A1 (en) * 1997-02-06 1998-08-13 Jonathan S. Stamler No-modified hemoglobins and uses therefor
WO1998050430A2 (en) * 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
US5900402A (en) 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6087087A (en) * 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
US6656452B1 (en) 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
US6089229A (en) 1998-05-26 2000-07-18 Datex-Ohmeda, Inc. High concentration no pulse delivery device
US6139506A (en) 1999-01-29 2000-10-31 Instrumentarium Oy Method for measuring pulmonary functional residual capacity
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US7516742B2 (en) 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
US6811778B2 (en) 2001-09-10 2004-11-02 Biopure Corporation Method for improving oxygen transport by stored red blood cells
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7485324B2 (en) * 2003-09-29 2009-02-03 Pulmonox Technologies Corporation Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms
WO2005077005A2 (en) 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
EP1799210A1 (en) 2004-10-05 2007-06-27 Bayer HealthCare AG A guanylate cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasconstriction
US7530353B2 (en) 2005-09-21 2009-05-12 The General Electric Company Apparatus and method for determining and displaying functional residual capacity data and related parameters of ventilated patients
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
KR20090087900A (ko) * 2006-11-07 2009-08-18 더 제너럴 하스피탈 코포레이션 혈관작용성 산소운반체에 의해 유도되는 혈관수축의 감소
DK3266463T3 (da) * 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5423738A (en) * 1992-03-13 1995-06-13 Robinson; Thomas C. Blood pumping and processing system
US20020037839A1 (en) * 1995-09-15 2002-03-28 Jonathan S. Stamler No-modified hemoglobins and uses therefor
WO2001009616A2 (en) * 1999-08-02 2001-02-08 Duke University Method for determining physiological effects of hemoglobin
WO2003066109A1 (en) * 2002-02-08 2003-08-14 Gambro, Inc. Nitric oxide in a pathogen inactivation process
WO2003102575A1 (en) * 2002-05-29 2003-12-11 Duke University Measuring nitric oxide in blood gases and treatments based thereon
US20100239692A1 (en) * 2007-09-20 2010-09-23 Kim-Shapiro Daniel B Methods of treatment for hemolysis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LESLEY J等: "Nitric oxide donors inhibit 5-hydroxytryptamine (5-HT) uptake by the human 5-HT transporter (SERT)", 《BRITISH JOURNAL OF PHARMACOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111919835A (zh) * 2020-08-06 2020-11-13 温州医科大学 维持红细胞活性的保存液
CN111919835B (zh) * 2020-08-06 2022-02-08 温州医科大学 维持红细胞活性的保存液

Also Published As

Publication number Publication date
EP2776047A1 (en) 2014-09-17
JP2014532764A (ja) 2014-12-08
US20140286921A1 (en) 2014-09-25
WO2013070592A1 (en) 2013-05-16
JP6389125B2 (ja) 2018-09-12
HK1200355A1 (en) 2015-08-07
EP2776047A4 (en) 2015-07-22
US9572833B2 (en) 2017-02-21

Similar Documents

Publication Publication Date Title
JP5769418B2 (ja) 選択的細胞吸着除去装置およびその関連方法
Henkel-Hanke et al. Artificial oxygen carriers: a current review
EP1229954B1 (en) Method of treating cardio pulmonary diseases with no group compounds
US9572833B2 (en) Treatment of red blood cells
CN111406737B (zh) 用于器官持续维持的成分、装置和方法
US12582674B2 (en) Methods and treatment of trauma
US20230248767A1 (en) Methods for Managing Adverse Events in Patients with Inflammation
Stollings et al. Oxygen therapeutics: Oxygen delivery without blood
ES2796962T3 (es) Filtro de sangre
Standl Artificial oxygen carriers as red blood cell substitutes–perfluorocarbons and cell-free hemoglobin
JP2005527834A (ja) 血液ガス中の一酸化窒素の測定およびそれに基づく処置
Wang Molecular mechanisms of surgery associated acute kidney injury (AKI) by blood degradation products in experimental mouse models
WO2024064723A1 (en) Oxygen reduced blood for use in the treatment of traumatic brain injury accompanied by hemorrhagic shock
Hanssen et al. NO-Ventilation Attenuates the Deleterious Effects of Cell-Free Hemoglobin on Microcirculatory Blood Flow and Injury in the Kidney

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141119